Halozyme Therapeutics Revenue by Segment

Period Ending	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023
Royalties	780.29M	699.31M	618.59M	570.99M	522.62M	482.00M	468.82M	447.87M
Royalties Growth	49.30%	45.09%	31.95%	27.49%	21.04%	15.61%	20.05%	24.24%
Product Sales	333.14M	325.57M	322.95M	303.49M	303.73M	303.64M	298.64M	300.85M
Product Sales Growth	9.68%	7.22%	8.14%	0.88%	7.55%	18.02%	30.02%	57.49%
Revenues Under Collaborative Agreements	129.42M	153.79M	142.77M	140.84M	121.00M	87.67M	95.53M	80.53M
Revenues Under Collaborative Agreements Growth	6.96%	75.42%	49.45%	74.88%	81.95%	-11.86%	12.67%	-25.85%

Operating Expense Breakdown

Period Ending	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019	Dec 31, 2018
Cost of Sales	192.06M	186.24M	179.49M	159.42M	169.66M	175.06M	185.52M	192.36M
Cost of Sales Growth	13.20%	6.39%	-3.25%	-17.13%	-6.87%	0.22%	17.01%	38.09%
Selling, General, and Administrative	172.31M	167.47M	161.56M	154.34M	149.69M	143.72M	146.96M	149.18M
Selling, General, and Administrative Growth	15.11%	16.52%	9.94%	3.45%	0.25%	-3.23%	-12.03%	3.94%
Amortization	71.05M	71.05M	71.05M	71.05M	71.05M	73.63M	73.70M	73.77M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Amortization Growth	-0.00%	-3.50%	-3.60%	-3.69%	17.31%	9.22%	20.85%	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Research and Development	70.03M	71.24M	74.74M	79.05M	79.94M	78.81M	77.50M	76.36M
Research and Development Growth	-12.40%	-9.60%	-3.56%	3.52%	3.03%	2.38%	6.55%	14.65%

Source: Business metrics provided by Main Street Data and sourced from official company press releases and documents.